Sunday, October 1, 2023
Read Overview
Supported by an independent educational grant from Lilly.
Rapid Fire
The Year in Review
New Challenge
New Challenge
New Challenge
Steering Committee Chair
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas, United States
Steering Committee Chair
Director
Breast Center
Department of Obstetrics and Gynecology
LMU University Hospital
Munich, Germany
Professor
University of Milan
Director, Division of Early Drug Development
European Institute of Oncology
Milan, Italy
Director
Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee, United States
Professor of Breast Cancer Medicine
Head of Medical Oncology
Consultant Medical Oncologist
Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
London, United Kingdom
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Steering Committee Chair
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Agendia; Amgen Biotechnology; Aptitude Health; AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; Carrick Therapeutics; Celgene Corporation; Daiichi Sankyo; Eisai Inc.; Fishawack Health; G1 Therapeutics; GlaxoSmithKline; Genentech; Genzyme Corporation; Gilead Sciences; Immunomedics, Inc.; Incyte Corporation; Lilly; Merck; Novartis; Ontada; Pfizer Inc.; Pharmacyclics, Inc.; Pierre Fabre Pharmaceuticals; Puma Biotechnology; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen, Inc.; Stemline Therapeutics; Synthon
Steering Committee Chair
Has the following relevant financial relationships:
Consultant or advisor for: Gilead Sciences, Inc.; Novartis; Roche; Sandoz; Sanofi; Seagen, Inc.
Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Novartis; Pierre Fabre Pharmaceuticals; Pfizer Inc.; Roche; Sandoz; Sanofi; Seagen, Inc.; Viatris
Research funding from: AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Daiichi Sankyo; Merck Sharp & Dohme; Pfizer Inc.; Roche
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Daichii Sankyo; Gilead Sciences, Inc.; Lilly; Menarini; Novartis; Pfizer Inc.
Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Daichii Sankyo; Gilead Sciences, Inc.; Lilly; Menarini; Novartis; Pfizer Inc.
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: Arcus; Arvinas; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; Greenwich LifeSciences; iTeos; Janssen Biotech, Inc.; Lilly; Loxo Oncology; Mersana Group; Novartis Oncology; Orum Therapeutics; Pfizer, Inc.; Relay Therapeutics; Roche; Seagen Inc.; Verascity Science
Research funding from: AbbVie Inc.; Accutar Biotechnology; Acerta Pharma; ADC Therapeutics; AKESOBIO Australia; Amgen, Inc.; Aravive; ArQule; Artios; AstraZeneca; AtlasMedx; BeiGene (Beijing) Co., Ltd; Black Diamond; Bliss Biopharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Context Therapeutics; Cullinan; Curis, Inc.; CytomX Therapeutics; Daiichi Sankyo, Inc.; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology; EMD Serono, Inc.; FujiFilm; G1 Therapeutics; Genentech, Inc.; H3 Biomedicine; Harpoon; Hutchinson MediPharma; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte Corporation; Infinity Pharmaceuticals, Inc.; InventisBio; Jacobio; Karyopharm; K-Group Beta; Kind Pharmaceuticals; Leap Therapeutics, Inc.; Lilly; Loxo Oncology; Lycera; Mabspace Biosciences; Macrogenics; MedImmune Inc.; Mersana Group; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates; Novartis Oncology; Nucana; Olema; OncoMed; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals; Orinove; Orum Therapeutics; Pfizer, Inc.; PharmaMar; Pieris Pharmaceuticals; Pionyr Immunotherapeutics; Plexxikon Inc.; Prelude Therapeutics; Profound Bio; Radius Health, Inc.; Regeneron Pharmaceuticals, Inc.; Relay Therapeutics; Repertoire Immune Medicine; Rgenix; Roche; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs, Inc.; StemCentRx; Sutro Biopharma, Inc.; Syndax; Syros; Taiho Pharmaceutical Co., Ltd.; TapImmune; TESARO, Inc.; Tolmar; Torque Therapeutics; Treadwell Therapeutics; Verastem, Inc.; Zenith Epigenetics; Zymeworks
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: Eli Lilly; Novartis; Pfizer Inc.; Puma Biotechnology; Sanofi Genzyme Corporation (former)
Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Eisai Inc.; Eli Lilly; Novartis; Pfizer Inc.; Roche/Genentech (former); Sanofi Genzyme Corporation (former)
Research funding from: AstraZeneca Pharmaceuticals LP; Eli Lilly; Novartis; Pfizer Inc.; Puma Biotechnology
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: 4D Pharma; Aadi Biopharma; ARC Therapeutics; Artios Pharma; AstraZeneca Pharmaceuticals LP; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol Myers Squibb Company; CytomX Therapeutics; Daichii Sankyo; Eisai Inc.; Eli Lilly; Ellipeses Pharma; Genentech/Roche; Gilead Sciences, Inc.; Incyte Corporation; Infinity Therapeutics; Menarini/Stemline; Merck; Myovant Sciences Ltd.; Novartis; OncoSec Medical Inc.; OncXerna; Pfizer Inc.; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research funding from: AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Eisai Inc.; Exelixis, Inc.; Genentech/Roche; Gilead Sciences, Inc.; Lilly; Merck; NanoString Technologies; Novartis; OncoPep; Pfizer Inc.; Seattle Genetics, Inc.